Welcome to Panacea Infarm
Opening Hours : Monday to Saturday - 8am to 9pm
Contact : +6 1385 9264 66
News
Jun
21

New equipment and capacities in the fight against hepatitis B and other incurable diseases

Hepatitis B virus (HBV) causes an infectious disease in humans with a damaging effect on the liver. The virus is transmitted parenterally through blood and plasma, through sexual contacts, causes discomfort, and is a threat to life. According to statistics, about 1 million people worldwide die from hepatitis B every year.

Read more
Dec
27

The generic Meravir drug will safe Russia from hepatitis B

The Australian company Panacea Infarm is a major player in the biopharmaceutical market engaged in the development of various drugs. The company has announced its plans to transfer the right to manufacture generic of its drug no earlier than one year from now.

Read more
Nov
16

The cost of Meravir will be even lower for countries with a low standard of living

Panacea Infarm has announced a price reduction for Merovir for countries with a low standard of living (Russia, CIS, some European countries, South America, African countries).

Read more
Oct
14

New shape and color of pills from November 2021

Panacea Infarm company reports that color and shape of pills in the new batch released in November 2021 will have new shape and color
It is connected with production re-equipment and purchase of new components and dyes

Read more
Jun
28

According to the clinical studies results the effectiveness of the drug FABI256 reaches 85%

Scientists got the clinical trials results of the drug FABI256 aimed to treat chronic viral hepatitis B and D.

Read more
May
23

Meravir production stopped

The production of Meravir has been discontinued indefinitely. Due to the coronavirus pandemic, all the capacities of Panacea Infarm are aimed at the development and production of drugs for the treatment of coronavirus. The last batch of the drug was distributed among WHO charitable organizations around the world.

Read more
May
18

Hepatitis B treatment is too expensive: Panacea Infarm is forced to reduce the price of Meravir

Hepatitis B is recognized as a global epidemic due to its high prevalence and a major risk of being affected by a virus. Until recently, the disease was considered incurable.

Read more
Jun
30

A new cure strategy for hepatitis B using the most effective drug Meravir

Hepatitis B is the only virus coping with the existing vaccine against it, still continuing to kill millions of people worldwide. Today Hepatitis B drugs represent a separate pharmaceutical market.

Read more
Dec
25

Attention and Excitement are growing: the release of the drug for hepatitis B is coming closer

 25.12. 2018

Hepatitis B incidence statistics are depressing, to put it mildly. According to the results of a large-scale study published in The Lancet Gastroenterology & Hepatology, only 1 out of 20 patients with the virus among the 300 million infected receives the required treatment.

Read more
Feb
25

The clinical trials of the hepatitis B drug FABI256 with the participation of people have started

Statistics show that more than 1 million people worldwide dies from different hepatitis B effects. According to Rospotrebnadzor (Federal Service for Consumer Rights Protection and Human Welfare in Russian Federation), in 2017 over 14,000 cases of chronic hepatitis B were registered in Russia, 1.3 thousand people suffers from an acute condition of this disease. All that the contemporary pharmaceutical market can offer such patients today is medicines suppressing the virus but not destroying it. 

Read more